Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Cell Tissue Res ; 336(1): 67-77, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19214581

RESUMEN

Our aim has been to characterize the molecular mechanisms regulating the expression of the channel-forming tight-junctional protein claudin-2 in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNFalpha), which is elevated, for example, in active Crohn's disease. TNFalpha caused an 89% decrease of the paracellular resistance in colonic HT-29/B6 cells, whereas transcellular resistance was unaltered. The claudin-2 protein level was increased by TNFalpha without changes in subcellular tight-junctional protein localization as revealed by confocal laser scanning microscopy. Enhanced gene expression was identified as the source of this increase, since claudin-2-specific mRNA and promoter activity was elevated, whereas mRNA stability remained unaltered. Specific inhibitors and phospho-specific antibodies revealed that the increased gene expression of claudin-2 after TNFalpha treatment was mediated by the phosphatidylinositol-3-kinase pathway. Thus, the up-regulation of claudin-2 by TNFalpha is attributable to the regulation of the expression of the gene, as a result of which epithelial barrier function is disturbed, for example, during chronic intestinal inflammation.


Asunto(s)
Proteínas de la Membrana/genética , Fosfatidilinositol 3-Quinasas/fisiología , Factor de Necrosis Tumoral alfa/farmacología , Cromonas/farmacología , Claudinas , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Células HT29 , Humanos , Mucosa Intestinal/metabolismo , Proteínas de la Membrana/metabolismo , Morfolinas/farmacología , Fosfatidilinositol 3-Quinasas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Transducción de Señal/efectos de los fármacos , Uniones Estrechas/genética , Uniones Estrechas/metabolismo , Distribución Tisular , Regulación hacia Arriba/efectos de los fármacos
2.
J Cell Sci ; 113 ( Pt 11): 2085-90, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10806119

RESUMEN

The 65 kDa protein occludin is a membrane-spanning part of the epithelial tight junction, which is the main barrier of the paracellular pathway. The function of occludin as part of tight junctions is still poorly understood and even less is known about the regulatory mechanisms that influence occludin gene expression. This study aimed to identify the sequences essential in cis for genomic regulation of tight junction formation and to investigate their funcional role in cytokine-dependent tight junction regulation. Using genome walking cloning of occludin-specific human genomic DNA sequences, a 1853 bp DNA fragment containing the transcription start point of occludin cDNA sequences was amplified and sequenced. Subcloning of this fragment in front of the luciferase reporter gene revealed strong expression of enzymatic activity after transfection of the human intestinal cell line HT-29/B6. With subsequent deletions of parts of the promoter fragment, its size was reduced to 280 bp that are necessary and sufficient to mediate promoter activity. Tumor necrosis factor alpha and another cytokine involved in inflammation, interferon gamma, reduced transepithelial resistance in HT-29/B6 cells, which was preceded by a decrease in occludin mRNA expression as revealed by northern blot analysis. Tumor necrosis factor alpha and interferon gamma diminished occludin promoter activity alone and even synergistically, suggesting a genomic regulation of alterations of the paracellular barrier. In conclusion, proinflammatory cytokines such as tumor necrosis factor alpha and interferon gamma can downregulate the expression of the transmembrane tight junction strand protein occludin, paralleling the barrier disturbance detected electrophysiologically. This could be an important mechanism in gastrointestinal diseases accompanied by barrier defects, for example inflammatory bowel diseases.


Asunto(s)
Interferón gamma/farmacología , Proteínas de la Membrana/genética , Regiones Promotoras Genéticas/genética , Factor de Necrosis Tumoral alfa/farmacología , Secuencia de Bases , Células Epiteliales/fisiología , Eliminación de Gen , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Genes Reporteros , Células HT29 , Humanos , Luciferasas/genética , Datos de Secuencia Molecular , Ocludina , Regiones Promotoras Genéticas/efectos de los fármacos , ARN Mensajero/análisis , Uniones Estrechas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA